Mirum Pharmaceuticals, Inc.
brelovitug
chronic hepatitis delta virus (HDV)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for brelovitug in chronic hepatitis delta virus (HDV) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Brelovitug AZURE-1 study in chronic hepatitis delta virus (HDV) interim data expected in Q2 2026.”